Reverse Split and Spend Reporting

Quote




anonymous said:
Ah, another moron who knows nothing about the stock market. Can't take everything for face value. Today marked the end of our quiet period. Over next couple days, reports and analysts will come out to give market reports, projections, venture cap. firms who backed us will speak, Q2 earnings etc will all come out. Our stock is sitting at $18 which is exactly where they expected it to be. The stock will rise now that quiet period is over. Not to mention, look at biotech as a whole, all the stock are down 3-15%. It's an ebb and flow, very cyclic. But, you can't be blamed for your incompetence. You are, after all, a life time sales rep with little to no business accunem.
Click to expand...


It's "acumen" moron....learn how to spell before you go to business school. Also, who do you think is making all the money out there...life time sales reps...
 









anonymous said:
Ah, another moron who knows nothing about the stock market. Can't take everything for face value. Today marked the end of our quiet period. Over next couple days, reports and analysts will come out to give market reports, projections, venture cap. firms who backed us will speak, Q2 earnings etc will all come out. Our stock is sitting at $18 which is exactly where they expected it to be. The stock will rise now that quiet period is over. Not to mention, look at biotech as a whole, all the stock are down 3-15%. It's an ebb and flow, very cyclic. But, you can't be blamed for your incompetence. You are, after all, a life time sales rep with little to no business accunem.
Click to expand...
 



As an equities trader I have to respond to this post. This company is in the same space as Sequenom. What makes you think you are not going to experience the same market challenges? First thing is you guys were running on Venture Capital money when you were private. The reason you went with an IPO was the VC money would no longer support you. You will now learn a few things about your company that is alarming. Cash Burn Rate will be several million dollars a month. Managed care takes a long time to pony up reimbursements and to secure contracts. ACOG shot down general population so this will dry up because patients don't like OOP. At the same time you will be venturing into the oncology market with RSU tests. Absolute money up in smoke with that journey. Look for additional secondary offerings to raise more money to stay afloat in the future. From there you will learn about earnings dilution. You guys are years away from profitability.
The same hedge funds that short Sequenom are most likely starting to drive your stock price down. Those guys know where to hunt money and your company is a prime target. I can tell you for a fact if you dump two thousand shares short on the bid it will drop. Then drop three thousand shares on the bid again it will drop even more. If the stock tries to bounce from the fifty cent loss it just incurred. The short seller goes on the offer with the five thousand he just shorted and the stock cannot recover. Your stock is not under much accumulation for the sheer fact of how thinly it trades. No institutional support makes it easy to manipulate and the ALGO that trades your stock is not very challenging to figure out.
As far as eighteen becoming support, did you see someone sitting on the bid on Level 2 quotes with an unusual hold? What are you basing your prediction of a bottom here. I think this stock is going lower from here, a lot lower.
 



anonymous said:
As an equities trader I have to respond to this post. This company is in the same space as Sequenom. What makes you think you are not going to experience the same market challenges? First thing is you guys were running on Venture Capital money when you were private. The reason you went with an IPO was the VC money would no longer support you. You will now learn a few things about your company that is alarming. Cash Burn Rate will be several million dollars a month. Managed care takes a long time to pony up reimbursements and to secure contracts. ACOG shot down general population so this will dry up because patients don't like OOP. At the same time you will be venturing into the oncology market with RSU tests. Absolute money up in smoke with that journey. Look for additional secondary offerings to raise more money to stay afloat in the future. From there you will learn about earnings dilution. You guys are years away from profitability.
The same hedge funds that short Sequenom are most likely starting to drive your stock price down. Those guys know where to hunt money and your company is a prime target. I can tell you for a fact if you dump two thousand shares short on the bid it will drop. Then drop three thousand shares on the bid again it will drop even more. If the stock tries to bounce from the fifty cent loss it just incurred. The short seller goes on the offer with the five thousand he just shorted and the stock cannot recover. Your stock is not under much accumulation for the sheer fact of how thinly it trades. No institutional support makes it easy to manipulate and the ALGO that trades your stock is not very challenging to figure out.
As far as eighteen becoming support, did you see someone sitting on the bid on Level 2 quotes with an unusual hold? What are you basing your prediction of a bottom here. I think this stock is going lower from here, a lot lower.
Click to expand...

Wow, as an equities trader, I guess we will have to take your word for how our company is going to perform, including the "money up in smoke journey" that our oncology screening will bring. You must know so much about the biotech space and the technology behind both Seqn and Natera. Our company is in the same space, but we are mutually exclusive. Let's not pretend that just because two companies are in the same space means they will have the same outcomes or even challenges. Yes, it is a challenge at the end of the day, but I think general counsel and the VC's backing have done enough research to know what is going on and there is a plan. As you look for your next big payday with all your fancy wall st talk, I'll continue to go and help a family cope with the fact that our test just delivered a non-welcoming result that other screens would have never picked up. Maybe a couple families here and there will be worth it in the end.
 



anonymous said:
Wow, as an equities trader, I guess we will have to take your word for how our company is going to perform, including the "money up in smoke journey" that our oncology screening will bring. You must know so much about the biotech space and the technology behind both Seqn and Natera. Our company is in the same space, but we are mutually exclusive. Let's not pretend that just because two companies are in the same space means they will have the same outcomes or even challenges. Yes, it is a challenge at the end of the day, but I think general counsel and the VC's backing have done enough research to know what is going on and there is a plan. As you look for your next big payday with all your fancy wall st talk, I'll continue to go and help a family cope with the fact that our test just delivered a non-welcoming result that other screens would have never picked up. Maybe a couple families here and there will be worth it in the end.
Click to expand...

omg......even with a more honest upfront look at our company .... our resident company cheerleader still feels the need to respond. the more you keep talking the more i'm beginning to know who you are. i think you're a freakin joke.
 






anonymous said:
omg......even with a more honest upfront look at our company .... our resident company cheerleader still feels the need to respond. the more you keep talking the more i'm beginning to know who you are. i think you're a freakin joke.
Click to expand...

You're beginning to know who I am? Oh really?! Or, you think you know who I am? Not sure how you can begin to know who I am...wouldn't you just think you know or know? How does beginning the process go? What region do you think I reside in? What if I'm not an employee at all? Maybe an optimistic share holder?
 



anonymous said:
You're beginning to know who I am? Oh really?! Or, you think you know who I am? Not sure how you can begin to know who I am...wouldn't you just think you know or know? How does beginning the process go? What region do you think I reside in? What if I'm not an employee at all? Maybe an optimistic share holder?
Click to expand...

What if that was too many questions?
 



anonymous said:
omg......even with a more honest upfront look at our company .... our resident company cheerleader still feels the need to respond. the more you keep talking the more i'm beginning to know who you are. i think you're a freakin joke.
Click to expand...

Why are you so upset that you just aren't that good at your job? I promise, I know for a fact......you mom loves you.
 












anonymous said:
As an equities trader I have to respond to this post. This company is in the same space as Sequenom. What makes you think you are not going to experience the same market challenges? First thing is you guys were running on Venture Capital money when you were private. The reason you went with an IPO was the VC money would no longer support you. You will now learn a few things about your company that is alarming. Cash Burn Rate will be several million dollars a month. Managed care takes a long time to pony up reimbursements and to secure contracts. ACOG shot down general population so this will dry up because patients don't like OOP. At the same time you will be venturing into the oncology market with RSU tests. Absolute money up in smoke with that journey. Look for additional secondary offerings to raise more money to stay afloat in the future. From there you will learn about earnings dilution. You guys are years away from profitability.
The same hedge funds that short Sequenom are most likely starting to drive your stock price down. Those guys know where to hunt money and your company is a prime target. I can tell you for a fact if you dump two thousand shares short on the bid it will drop. Then drop three thousand shares on the bid again it will drop even more. If the stock tries to bounce from the fifty cent loss it just incurred. The short seller goes on the offer with the five thousand he just shorted and the stock cannot recover. Your stock is not under much accumulation for the sheer fact of how thinly it trades. No institutional support makes it easy to manipulate and the ALGO that trades your stock is not very challenging to figure out.
As far as eighteen becoming support, did you see someone sitting on the bid on Level 2 quotes with an unusual hold? What are you basing your prediction of a bottom here. I think this stock is going lower from here, a lot lower.
Click to expand...
 



anonymous said:
As an equities trader I have to respond to this post. This company is in the same space as Sequenom. What makes you think you are not going to experience the same market challenges? First thing is you guys were running on Venture Capital money when you were private. The reason you went with an IPO was the VC money would no longer support you. You will now learn a few things about your company that is alarming. Cash Burn Rate will be several million dollars a month. Managed care takes a long time to pony up reimbursements and to secure contracts. ACOG shot down general population so this will dry up because patients don't like OOP. At the same time you will be venturing into the oncology market with RSU tests. Absolute money up in smoke with that journey. Look for additional secondary offerings to raise more money to stay afloat in the future. From there you will learn about earnings dilution. You guys are years away from profitability.
The same hedge funds that short Sequenom are most likely starting to drive your stock price down. Those guys know where to hunt money and your company is a prime target. I can tell you for a fact if you dump two thousand shares short on the bid it will drop. Then drop three thousand shares on the bid again it will drop even more. If the stock tries to bounce from the fifty cent loss it just incurred. The short seller goes on the offer with the five thousand he just shorted and the stock cannot recover. Your stock is not under much accumulation for the sheer fact of how thinly it trades. No institutional support makes it easy to manipulate and the ALGO that trades your stock is not very challenging to figure out.
As far as eighteen becoming support, did you see someone sitting on the bid on Level 2 quotes with an unusual hold? What are you basing your prediction of a bottom here. I think this stock is going lower from here, a lot lower.
Click to expand...
 



anonymous said:
As an equities trader I have to respond to this post. This company is in the same space as Sequenom. What makes you think you are not going to experience the same market challenges? First thing is you guys were running on Venture Capital money when you were private. The reason you went with an IPO was the VC money would no longer support you. You will now learn a few things about your company that is alarming. Cash Burn Rate will be several million dollars a month. Managed care takes a long time to pony up reimbursements and to secure contracts. ACOG shot down general population so this will dry up because patients don't like OOP. At the same time you will be venturing into the oncology market with RSU tests. Absolute money up in smoke with that journey. Look for additional secondary offerings to raise more money to stay afloat in the future. From there you will learn about earnings dilution. You guys are years away from profitability.
The same hedge funds that short Sequenom are most likely starting to drive your stock price down. Those guys know where to hunt money and your company is a prime target. I can tell you for a fact if you dump two thousand shares short on the bid it will drop. Then drop three thousand shares on the bid again it will drop even more. If the stock tries to bounce from the fifty cent loss it just incurred. The short seller goes on the offer with the five thousand he just shorted and the stock cannot recover. Your stock is not under much accumulation for the sheer fact of how thinly it trades. No institutional support makes it easy to manipulate and the ALGO that trades your stock is not very challenging to figure out.
As far as eighteen becoming support, did you see someone sitting on the bid on Level 2 quotes with an unusual hold? What are you basing your prediction of a bottom here. I think this stock is going lower from here, a lot lower.
Click to expand...
 






anonymous said:
Ah, another moron who knows nothing about the stock market. Can't take everything for face value. Today marked the end of our quiet period. Over next couple days, reports and analysts will come out to give market reports, projections, venture cap. firms who backed us will speak, Q2 earnings etc will all come out. Our stock is sitting at $18 which is exactly where they expected it to be. The stock will rise now that quiet period is over. Not to mention, look at biotech as a whole, all the stock are down 3-15%. It's an ebb and flow, very cyclic. But, you can't be blamed for your incompetence. You are, after all, a life time sales rep with little to no business accunem.
Click to expand...
 



Top Bottom
Back
Quote